Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France

BMC Public Health

Research Article

Pierre Pradat¹  Xavier Carcopino²  André Dahlab³  Anne-Carole Jacquard³  François Aubin⁴  Didier Riethmuller⁵  Jean Lacau St Guily⁶  Jean-Luc Prétet⁷ 

[1] Department of Hepatology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France;Department of Obstetrics and Gynaecology, Hôpital Nord, Assistance Publique des Hôpitaux de Marseille (APHM), Aix-Marseille Université (AMU), CNRS, IRD, Avignon Université, IMBE UMR 7263, 13397, Marseille, France;Sanofi Pasteur MSD, 12 rue Jonas Salk, 69367, Lyon, Cedex 07, France;Service de dermatologie, Centre Hospitalier Universitaire Saint-Jacques, Besançon, France;Service de gynécologie obstétrique, CHU Saint Jacques, Besançon, France;Service d’Oto-rhino-laryngologie et chirurgie cervico-faciale, Hôpital Tenon, Université de Paris 6 et Faculté de Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, Paris, France;Université Franche-Comte, F-25000, Besançon, France;EA 3181, FED4234, LabEx LipSTIC ANR-11-LABX-0021, CIC-BT 506, F-25000, Besancon, France;CHRU Besançon, F-25000, Besançon, France;

关键词: HPV;    Human papillomavirus;    Vaccine;    Invasive cervical cancer;    Cervical intraepithelial neoplasia;    Genital warts;    Anal cancer;   

DOI  :  10.1186/s12889-015-1779-1

 received in 2015-01-27, accepted in 2015-04-22,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundHuman Papillomavirus (HPV) infection is known to be associated with a number of conditions including cervical, vaginal, vulvar, penile, anal neoplasias and cancers, oropharynx cancers and genitals warts (GW). Two prophylactic vaccines are currently available: a bivalent vaccine designed to prevent HPV type 16 and 18 infection and a quadrivalent vaccine targeting HPV 6, 11, 16, and 18. In France, HPV vaccination is recommended in 11-14 year-old girls with a catch-up for girls aged 15-19. The objective of this study was to assess the potential impact of an HPV 6/11/16/18/31/33/45/52/58 nonavalent vaccine on anogenital and oropharyngeal HPV-related diseases in France.MethodsHPV genotype distributions from 6 multicentric retrospective studies (EDiTH I to VI) were analyzed including 516 cases of invasive cervical cancers (ICC), 493 high-grade cervical neoplasias (CIN2/3), 397 low-grade squamous intraepithelial lesions (LSIL), 423 GW, 366 anal cancer and 314 oropharyngeal carcinomas. Low and high estimates of HPV vaccine impact were calculated as follows: low estimate: prevalence of HPV 6/11/16/18/31/33/45/52/58 genotypes alone or in association but excluding presence of another HPV type; high estimate: prevalence of HPV 6/11/16/18/31/33/45/52/58 genotypes alone or in association, possibly in presence of another HPV type.ResultsEstimates of potential impact varied from 85% (low estimate) to 92% (high estimate) for ICC, 77% to 90% for CIN2/3, 26% to 56% for LSIL, 69% to 90% for GW, 81% to 93% for anal cancer, and 41% to 44% for oropharyngeal carcinomas. Compared to the quadrivalent vaccine, the proportion of additional cases potentially prevented by the nonavalent vaccine was 9.9%-15.3% for ICC, 24.7%-33.3% for CIN2/3, 12.3%-22.7% for LSIL, 2.1%-5.4% for GW, 8.5%-10.4% for anal cancer, and 0.0%-1.6% for oropharyngeal carcinoma.ConclusionsThe nonavalent HPV vaccine showed significant increased potential impact compared to the HPV 6/11/16/18 quadrivalent vaccine for ICC, CIN2/3 and LSIL. Considering a 100% vaccine efficacy and high vaccine coverage, about 90% of ICC, CIN2/3, GW or anal cancer cases could be prevented by a nonavalent HPV vaccine in France.

【 授权许可】

Unknown   
© Riethmuller et al.; licensee BioMed Central. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.